On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...